237 related articles for article (PubMed ID: 33465670)
21. New monofunctional platinum(II) and palladium(II) complexes: Studies of the nucleophilic substitution reactions, DNA/BSA interaction, and cytotoxic activity.
Ćoćić D; Jovanović S; Radisavljević S; Korzekwa J; Scheurer A; Puchta R; Baskić D; Todorović D; Popović S; Matić S; Petrović B
J Inorg Biochem; 2018 Dec; 189():91-102. PubMed ID: 30243122
[TBL] [Abstract][Full Text] [Related]
22. Prostaglandin F
Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
[TBL] [Abstract][Full Text] [Related]
23. GLUT1-mediated selective tumor targeting with fluorine containing platinum(II) glycoconjugates.
Liu R; Fu Z; Zhao M; Gao X; Li H; Mi Q; Liu P; Yang J; Yao Z; Gao Q
Oncotarget; 2017 Jun; 8(24):39476-39496. PubMed ID: 28467806
[TBL] [Abstract][Full Text] [Related]
24. East-west fusion-necrosis and apoptosis acting in concert by demethylcantharidin-integrated platinum complexes.
Pang SK; So WK; Ho YP; Au-Yeung CF
Anticancer Agents Med Chem; 2014 Jun; 14(5):756-61. PubMed ID: 24476313
[TBL] [Abstract][Full Text] [Related]
25. Binding of platinum derivative, oxaliplatin to deoxyribonucleic acid: structural insight into antitumor action.
Ray B; Gupta B; Mehrotra R
J Biomol Struct Dyn; 2019 Sep; 37(14):3838-3847. PubMed ID: 30282523
[TBL] [Abstract][Full Text] [Related]
26. Novel Platinum(IV) complexes intervene oxaliplatin resistance in colon cancer via inducing ferroptosis and apoptosis.
Liu Z; Cai J; Jiang G; Wang M; Wu C; Su K; Hu W; Huang Y; Yu C; Huang X; Cao G; Wang H
Eur J Med Chem; 2024 Jan; 263():115968. PubMed ID: 37995563
[TBL] [Abstract][Full Text] [Related]
27. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
[TBL] [Abstract][Full Text] [Related]
28. New Pt-NNSO core anticancer agents: Structural optimization and investigation of their anticancer activity.
Chong SX; Jin Y; Au-Yeung SC; To KK
J Inorg Biochem; 2017 May; 170():34-45. PubMed ID: 28214754
[TBL] [Abstract][Full Text] [Related]
29. Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells.
Cetraz M; Sen V; Schoch S; Streule K; Golubev V; Hartwig A; Köberle B
Arch Toxicol; 2017 Feb; 91(2):785-797. PubMed ID: 27307157
[TBL] [Abstract][Full Text] [Related]
30. Anticancer kiteplatin pyrophosphate derivatives show unexpected target selectivity for DNA.
Kasparkova J; Kostrhunova H; Novohradsky V; Pracharova J; Curci A; Margiotta N; Natile G; Brabec V
Dalton Trans; 2017 Oct; 46(41):14139-14148. PubMed ID: 28972623
[TBL] [Abstract][Full Text] [Related]
31. Defining the role of MRP-mediated efflux and glutathione in detoxification of oxaliplatin.
Mohn C; Häcker HG; Hilger RA; Gütschow M; Jaehde U
Pharmazie; 2013 Jul; 68(7):622-7. PubMed ID: 23923647
[TBL] [Abstract][Full Text] [Related]
32. Antitumor Activity of Ruthenium(II) Terpyridine Complexes towards Colon Cancer Cells In Vitro and In Vivo.
Savic M; Arsenijevic A; Milovanovic J; Stojanovic B; Stankovic V; Rilak Simovic A; Lazic D; Arsenijevic N; Milovanovic M
Molecules; 2020 Oct; 25(20):. PubMed ID: 33066568
[TBL] [Abstract][Full Text] [Related]
33. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
[TBL] [Abstract][Full Text] [Related]
34. Platinum(IV) Complexes of
Papadia P; Micoli K; Barbanente A; Ditaranto N; Hoeschele JD; Natile G; Marzano C; Gandin V; Margiotta N
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230896
[TBL] [Abstract][Full Text] [Related]
35. Rational design of dicarboxylato platinum(II) complexes with purine-mimetic ligands as novel anticancer agents.
Hoffmann K; Wiśniewska J; Wojtczak A; Sitkowski J; Denslow A; Wietrzyk J; Jakubowski M; Łakomska I
J Inorg Biochem; 2017 Jul; 172():34-45. PubMed ID: 28477537
[TBL] [Abstract][Full Text] [Related]
36. Heterodinuclear Pt(iv)-Ru(ii) anticancer prodrugs to combat both drug resistance and tumor metastasis.
Ma L; Ma R; Wang Z; Yiu SM; Zhu G
Chem Commun (Camb); 2016 Sep; 52(71):10735-8. PubMed ID: 27506281
[TBL] [Abstract][Full Text] [Related]
37. Glucose conjugated platinum(II) complex: antitumor superiority to oxaliplatin, combination effect and mechanism of action.
Li H; Gao X; Liu R; Wang Y; Zhang M; Fu Z; Mi Y; Wang Y; Yao Z; Gao Q
Eur J Med Chem; 2015 Aug; 101():400-8. PubMed ID: 26177447
[TBL] [Abstract][Full Text] [Related]
38. DNA cleavage and antitumour activity of platinum(II) and copper(II) compounds derived from 4-methyl-2-N-(2-pyridylmethyl)aminophenol: spectroscopic, electrochemical and biological investigation.
Roy S; Maheswari PU; Lutz M; Spek AL; den Dulk H; Barends S; van Wezel GP; Hartl F; Reedijk J
Dalton Trans; 2009 Dec; (48):10846-60. PubMed ID: 20023915
[TBL] [Abstract][Full Text] [Related]
39. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
[TBL] [Abstract][Full Text] [Related]
40. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
